Transplant Utilization, Procedure Patterns And Patient Characteristics In North American Transplant Centers From 1994-2005  by Hahn, T. et al.
S198 Poster Session Ito mobilize or utilizing combination G-CSF and plerixafor for all
pts as upfront mobilization.
Mobilization and Collection
All Patients Plerixafor No PlerixaforPB CD34 day 4
\10 65 47 (72%) 18 (28%)
10-14 11 4 (36%) 7 (64%)
$15 58 3 (5%) 55 (95%)not done* 12 12 0
Day 1 Apheresis yield
(x10[6] CD34/kg)
\1 15 14 (93%) 1 (7%)
\1.5 33 25 (76%) 8 (24%)
$1.5 77 5 (6%) 72 (94%)*12 patients received Plerixafor on the evening of day 4 due to prior
failure to mobilize or high risk of failure111
THE IMPACT OF PRIOR EXPOSURE TO RITUXIMAB ON AUTOLOGOUS
STEM CELL TRANSPLANTATION IN PATIENTS WITH FOLLICULAR AND
TRANSFORMED LYMPHOMA
Muccilli, A.D., Doucette, S., McDiarmid, S., Huebsch, L.B., Sabloff, M.
The Ottawa Hospital, Ottawa, ON, Canada
Introduction: Addition of rituximab to chemotherapy (CT) for
follicular lymphoma (FL) has been shown to improve many outcome
parameters. Often, high-dose therapy is followed by autologous
stem-cell transplantation (ASCT) after 1, 2 or more relapses. Kang
et al. (BMT (2007) 40, 973) investigated whether prior exposure to
rituximab had any influence on a subsequent ASCT and found no
differences in the outcomes analyzed. However, there has been evi-
dence suggesting that that such prior exposure may alter the pheno-
type of these tumour cells so that they no longer express CD20, and
thus potentially altering their behaviour.
Methods:We performed a retrospective review on all patients hav-
ing received an ASCT at the Ottawa Hospital with an initial diagno-
sis of FL. They were grouped into four categories according to their
prior exposure to or lack of prior exposure to rituximab and accord-
ing to their pre-ASCT diagnosis, non-transformed FL (FL-NT) vs.
transformed (FL-T).
Results: 259 patients who underwent an autoHSCT for FL were di-
vided into 4 groups: 184 FL non-transformed (FL-NT) (31 patients
received rituximab and 153 did not), and 75 FL-transformed (FL-T)
(24 patients received rituximab and 51 did not). The 5-year progres-
sion-free survivals (PFS) were 61.2% and 27.6%, respectively
(p\0.0001) and the overall survivals (OS) were 72.5% and 39.3%,
respectively, (p\0.0001). In the FL-NT group, no differences ex-
isted in PFS or OS between FL-NT rituximab-naı¨ve and rituxi-
mab-treated patients (5-year PFS 61% vs. 64%, p5 0.69; 5-year
OS 73% vs. 68%, p5 0.80).Within the FL-T group, the subsequent
5-year PFS of the rituximab-naive vs. pre-treated groups were 22%
and 55% (p 50.20), respectively, and the 5-year OS were 36% and
51% (p5 0.39), respectively. Prior exposure to R had a positive ef-
fect (Hazard Ratio (HR): 0.44, 95% CI 0.20-0.97, p5 0.04) on
PFS and OS (HR: 0.5, 95% CI 0.21-1.18, p5 0.11).
Conclusion: Pre-treatment with rituximab in FL-NT prior to
ASCTdoes not adversely impact ASCToutcomes.There is a sugges-
tion of an increase in the number of patients with FL-T being trans-
planted in the post-rituximab era and as expected, the FL-T had
a poorer outcome than the FL-NT patients. However, prior expo-
sure to rituximab appeared to demonstrate a trend toward an im-
proved OS within the FL-T group. In summary, previous
rituximab exposuremay be associated with an increased rate of trans-
formation, leading to the poorer outcome of patients originally diag-
nosed with FL-NT.112
CD34 + ALDH+ PERIPHERAL BLOOD STEM CELLS IN CRYOPRESERVED
APHERESIS PRODUCT ARE NON-APOPTOTIC AND PREDICT EARLY AND
LATE ENGRAFTMENT FOLLOWING AUTOLOGOUS TRANSPLANTATION
Peters, L.1,2,3, Mossman, A.2,3, Brown, C.1, Wong, K.1, Ward, C.1,2,3,
Greenwood, M.1,2 1Royal North Shore Hospital, Sydney, NSW, Australia;
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Methods which permit discrimination between viable and apopto-
tic peripheral blood stem cells (PBSC) following cryopreservation
may be important in assessing the quality and engraftment potential
of thawed apheresis product used in autologous transplantation. Pre-
vious studies have shown that cryopreservation results in significant
apoptosis in CD34+ cells and that estimation of PBSC number based
on the expression of the functional stem cell marker, aldehyde dehy-
drogenase (ALDH)may provide a better estimate of engraftment po-
tential in cryopreserved product than CD34 alone. We assessed
whether PBSC subset assessment based upon DilC1, a sensitive
marker of mitochondrial membrane potential and apoptosis, to-
gether with the viability exclusion dye 7-AAD, ALDH activity and
CD34 expression may identify subsets which correlate with short
and long term engraftment parameters following cryopreservation
of PBSC apheresis product and autologous transplantation. 35 pts
(median age 596 9yrs) underwent PBSC collection, high dose che-
motherapy and autologous transplantation for haematological ma-
lignancy. Most pts had multiple myeloma (42%) or NHL (40%).
Post thaw mean infused CD34  106/kg was 4.10 (0.05-10.5) and
ALDH  106/kg 2.28 (0.25-6.5). CD34 viability was 72.3% (11.7-
96.0). Most ALDH+ cells were non-apoptotic as assessed by DilC1
staining, 89.9% (55.6-100.0) vs CD34, 34.5% (3.2-84.7),
(p\0.005), and most ALDH+ cells expressed CD34 (71.3%, 33.9-
97.2). Only the CD34 + ALDH+ subset correlated with time to
ANC. 0.5  109/L, (p5 0.049), though a trend was noted for
CD34 +DilC1+ (p5 0.07). No analysed subset could be significantly
correlated to short term platelet recovery (Pl. 20  10/9L). Long
term (day 100) erythroid (Hb .100 g/L) and platelet engraftment
(Pl. 100  109/L) was strongly correlated to numbers of
CD34 +DilC1+ (p\0.005), CD34 + ALDH+ (p\0.005), and
CD34 + ALDH+DilC1+ (p\0.005) in infused product. Assess-
ments of engraftment potential of cryopreserved PBSC’s based on vi-
able CD34 counts may be uninformative unless markers of apoptotic
activity are included for analysis. In contrast, assessments based on
ALDH activity appear to identify a viable and non-apoptotic stem
cell subset correlated to both short term neutrophil and long term
erythroid and platelet engraftment potential following autologous
transplantation. Markers of apoptosis may be redundant when as-
sessing ALDH activity in autologous PBSC product.113
TRANSPLANT UTILIZATION, PROCEDURE PATTERNS AND PATIENT
CHARACTERISTICS IN NORTH AMERICAN TRANSPLANT CENTERS FROM
1994-2005
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Joffe, S.5, Majhail, N.6 1Roswell Park Cancer Institute, Buffalo, NY;
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Autologous (Auto) and allogeneic (Allo) hematopoietic cell
transplantation (HCT) have been used to cure malignant and
non-malignant conditions for .40 years. Recent advances in
HCT techniques and supportive care, new HCT indications,
and improvements in survival outcomes may have increased access
to and utilization of HCT. We describe the HCT population, uti-
lization and procedure patterns in North American (US and Can-
ada) HCT centers reporting to the CIBMTR from 1994-2005.
We divided the population into six 2-year cohorts (Table). All
data exclude donor lymphocyte infusions. The number of Au-
toHCTs increased by .30% from the mid to late 1990s, then
1994-95 1996-97 1998-99 2000-01 2002-03 2004-05
N (%) N (%) N (%) N (%) N (%) N (%)
# of patients
Total 15,603 19,765 20,260 15,989 16,125 18,244
AutoHCT 10,557 (68) 13,628 (69) 13,931 (69) 9,602 (60) 9,449 (59) 10,918 (60)
AlloHCT 5,046 (32) 6,137 (31) 6,329 (31) 6,387 (40) 6,676 (41) 7,326 (40)
Median (range) Age, years
AutoHCT 44 (\1-75) 46 (\1-76) 48 (\1-78) 50 (\1-78) 52 (\1-91) 53(\1-81)
AlloHCT 33 (\1-68) 35 (\1-79) 37 (\1-76) 39 (\1-79) 40 (\1-76) 40 (\1-78)
AutoHCT graft source
Marrow 2,730 (26) 1,470 (11) 651 ( 5) 296 ( 3) 193 ( 2) 208 ( 2)
Blood 6,288 (60) 11,216 (82) 12,773 (92) 9,020 (94) 9,104 (96) 10,618 (97)
Marrow1 Blood 1,539 (15) 942 ( 7) 507 ( 4) 286 ( 3) 151 ( 2) 92 ( 1)
AlloHCT graft source
Marrow 4,571 (91) 4,693 (76) 4,420 (67) 2,834 (46) 2,111 (32) 1970 (27)
Peripheral Blood 357 ( 7) 1,129 (18) 1,640 (26) 2,996 (47) 3,912 (59) 4,588 (63)
Marrow1 Blood 33 ( 1) 36 ( 1) 45 ( 1) 26 (\1) 11 (\1) 27 (\1)
Cord Blood 85 ( 2) 279 ( 5) 404 ( 6) 531 ( 8) 642 (10) 741 (10)
AlloHCT donor relationship
HLA-identical Sibling 2,999 (59) 3,555 (58) 3,547 (56) 3,443 (54) 3,400 (51) 3,255 (44)
Unrelated 1,237 (25) 1,802 (29) 2,024 (32) 2,182 (34) 2.616 (39) 3,273 (45)
Other Relative 614 (12) 623 (10) 575 ( 9) 590 ( 9) 496 ( 7) 525 ( 7)
Other 25 ( 1) 18 (\1) 19 (\1) 61 ( 1) 87 ( 1) 160 ( 2)
Missing 171 ( 3) 139 ( 2) 164 ( 3) 111 ( 2) 77 ( 1) 113 ( 2)
Meta-analysis: CR and 2 yr OS post ASCTwith baseline lym-
phoma status
Poster Session I S199declined by .30% in the early 2000s, but rose again in 2004-5.
Most of this change is due to a decrease in AutoHCT for breast
cancer from 42% in 1994-5 to 1% in 2004-5. In this same period,
AutoHCT increased for MM (6% to 44%) and NHL/HL (33%
to 41%), whereas acute or chronic leukemia decreased from 8%
to 5% and solid tumors remained stable at 9%. The number of
AutoHCTs for the new indication of autoimmune diseases have
totaled 146 from 1996-2005. The number of AlloHCTs increased
by 45% over this 12-year period, mostly due to a 2.6-fold increase
in unrelated donor AlloHCTs. From 1994-5 to 2004-5, AlloHCT
increased for AML/ALL (43% to 51%), MDS/MPS (8% to 11%),
and NHL/HL (8% to 12%), but decreased for CML (23% to 8%)
and MM (5% to 1%). AlloHCT conditioning regimen intensity
was 100% myeloablative in 1994-5, whereas reduced intensity/
nonmyeloablative regimens were used in 28% of AlloHCTs in
2004-5. The use of peripheral blood and cord blood have dramat-
ically increased. The median age and upper age limit have in-
creased for both AutoHCT and AlloHCT. The percent of non-
White race recipients increased from 1994-5 to 2004-5 for both
autoHCT (8 to 17%) and AlloHCT (14 to 19%). In the entire
study period, there have been 2,115 planned tandem AutoHCTs,
242 planned tandem Auto/AlloHCTs, 48 planned tandem Allo/Al-
loHCTs, 1,135 unplanned Auto/AutoHCTs, 1,559 unplanned
Auto/AlloHCTs, 2,091 unplanned allo/AlloHCTs, and 2,828
other multiple HCTs (unknown if planned or unplanned). The
HCT population has changed dramatically over time. Further
analyses are ongoing to determine the impact of these changes
on the success of HCT.CR post
ASCT
2 year
OS Lymphoma Status Entering ASCT
Rate
(%) 70.5 70.9
1st
CR5 16%
.CR1
5 8%
PR, CS
5 25%
Relapse
NOS
5 27%
PD/
refractory
5 16%
95%
Conf.
Int.
59.5-79.5 60.9-79.2
CR5 complete remission, PR5 partial remission, CS5 chemosensi-
tive, PD5 progressive disease114
AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR HIV-RELATED
LYMPHOMAS IN THE HAART ERA: A META-ANALYSIS OF RESPONSE AND
SURVIVAL POST TRANSPLANT
Sunil, M.1, Reid, E.G.2, Lechowicz, M.1 1Winship Cancer Institute
Emory University, Atlanta, GA; 2Moores Cancer Center University of
California San Diego, CA
Introduction: Recently data has shown survival and response rates
in small numbers of HIV patients receiving ASCT for HL andNHL in the HAART era. We did a comprehensive review and
meta-analysis of the literature to examine collective therapeutic out-
comes and survival.
Methods:We searched OVID, PUBMED, Google Scholar (1980 –
Sept 2009), ASH (2004-8), ASCO (2004-9), and BMT Tandem
(2005-9) annual meeting abstracts for references. Articles obtained
were reviewed for additional references. Inclusion criteria: 1) Autol-
ogous transplants for HIV/AIDS associated lymphoma with
HAART 2) Reported in English 3) Studies reporting: complete re-
sponse rates (CR), and one or more survival statistics. 4) Compre-
hensive trials, cohort studies or case series. Authors were queried
for possible patient overlap among studies. Primary outcome mea-
sures were response to ASCT and 2 year overall survival rates (OS).
Results: Out of 61 references, 14 studies were on ASCT in HIV
related lymphoma and 13 case reports. 5 met inclusion criteria.
These included 35 Hodgkins and 83 NHL subjects. CR rates
post ASCT 71% (95%CI 60-80), 2 year OS of 71% (95%CI
61-79) (see Table). Subjects entering ASCT in CR had a post
ASCT CR rate of 91%, and a 2 year OS rate of 70%. Compared
to subjects without CR when entering ASCT, those in CR at time
of ASCT were 8-fold more likely to be in CR post ASCT and 3-
fold likelihood of being alive at 2 years post ASCT. Difference in
survival were not apparent between transplantation in CR1, CR2,
or greater than CR2. Achievement of CR appears to be predictive
